OLYMPUS On-Demand Library
Add to View

Gastric Cases 8

Prof. Dr. Liu Zhiguo ​

​Hp-eradicated gastric cancer

Procedure Information


Scope: GIF-H290Z

Case: Early stomach cancer (M cancer)

Organ: Stomach

Patient Information: M, 50

Medical History: Early esophageal cancer was resected by ESD 10 years ago, the patient was followed up since then. A 0-IIc lesion 10mm was found in lesser curvature below the cardia 1 year ago with biopsy confirming atrophic gastritis with intestinal metaplasia, a biopsy was taken 1 month ago suggested epithelial low-grade neoplasia.

1. WLI observation

#Structure enhancement: A7 #Color mode1

Remarkable redness of a 0-IIc lesion was seen in the lesser curvature area below the cardia.

2. WLI observation

#Structure enhancement: A7 #Color mode1

An flat elevation was observed on the anal side

3. WLI observation

#Structure enhancement: A5 #Color mode1

No lesion was seen in the same area 4 years ago

4. NBI observation

#Structure enhancement: A8 #Color mode1

The lesion showed a brownish tone surrounded by a blue-green mucosa under NBI.

5. NBI observation

#Structure enhancement: A8 #Color mode1

Magnified view showed clear margin on the oral side, irregular pattern on the surface structure in depressed area, and unclear MCEs.

6. NBI observation

#Structure enhancement: A8 #Color mode1

Underwater magnification reveals dilated and distorted microvessels with markedly increased density.

7. NBI observation

#Structure enhancement: A8 #Color mode1

The lesion shown flat elevation on the anal side.

8. NBI observation

#Structure enhancement: A8 #Color mode1

Magnification on the anal side reveals poorly defined margin, with enlarged glands mixed with small irregular glands.

9. NBI observation

#Structure enhancement: A8 #Color mode1

Underwater magnification reveals dilated and distorted microvessels with markedly increased density.

10. RDI observation

#RDI mode 2

RDI mode 2 was used to differentiate submucosal vessels during resection.

11. Crystal violet staining

#Structure enhancement: A7 #Color mode1

Specimens were stained using crystal violet to show the extent of the lesion. Marking spot is visible in the lower right of the figure.

12. Crystal violet staining

#Structure enhancement: A5 #Color mode1

Low magnification shows alterations in the structure of the gland in the central area of lesion.

Case video

ESD under RDI showed a possibility to effectively improve the visibility of submucosal blood vessels.

Overall Comment

This is a case of gastric cancer after HP eradication found after 10-year follow-up after ESD resection for early esophageal cancer.

During the follow-up, breath test was negative, the level of pepsinogen I was significantly reduced (30-40ng/ml), and atrophy was graded as C3. One year before the ESD procedure, a reddish 0-IIc lesion was found below the cardia, and biopsy suggested atrophic gastritis, and another biopsy 1 month ago suggested epithelial neoplasia with low atypia, which was considered to be a neoplastic lesion. Elevation of anal side was clear after 1-year follow-up, and the lesion showed significant redness, so endoscopic resection was recommended. The possibility of submucosal infiltration was not excluded due to the macrotypic manifestion of the lesion.

The pathology result of the resected lesion showed intramucosal carcinoma (tub1>pap, MM, pHM0, pVM0, UL-, ly-, v-, pT1aNx). The lesion was well demarcated under non-magnifying observation of resected specimen, but magnifying observation showed hyperplastic glands mixed with carcinoma, consistent with gastric cancer after Hp eradication. Elevation on the anal side was considered an artifact caused by the accumulation of adipose tissue and dilated submucosal blood vessels. Due to the rich vascularity of the lesion, massive bleeding occurred during resection, and RDI helped to distinguish the submucosal vessels, especially the bleeding point to facilitate better hemastatis in time.

Disclaimer: Any content or information (“Content”) presented herein is illustrative in nature and does not guarantee or represent specific information, outcomes, or results. Olympus Corporation, its subsidiaries, affiliates, directors, officers, employees, agents, and representatives (collectively “Olympus”) does not represent to or warrant the accuracy or applicability of the Content. Under no circumstances shall Olympus be liable for any costs, expenses, losses, claims, liabilities, or other damages (whether direct, indirect, special, incidental, consequential, or otherwise) that may arise from, or be incurred in connection with, the Content or any use thereof.